Trial Profile
A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 25 Sep 2009 New trial record.